CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy
2014 · Molecular Therapy · 281 citations
https://doi.org/10.1038/mt.2014.160
C
Christine E. Engeland
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
71
Papers
1.5K
Citations
21
h-index
27
i10-index
Christine E. Engeland is an academic researcher from Witten/Herdecke University. The author has contributed to research in topics: Virus-based gene therapy research & CAR-T cell therapy research & Cancer Research and Treatments. The author has an h-index of 21, co-authored 61 publications.
ORCID: 0000-0001-6032-8786Papers by this author
worksGranulocyte-Macrophage Colony-Stimulating Factor-Armed Oncolytic Measles Virus Is an Effective Therapeutic Cancer Vaccine
2013 · Human Gene Therapy · 95 citations
https://doi.org/10.1089/hum.2012.205
Enhanced Control of Oncolytic Measles Virus Using MicroRNA Target Sites
2018 · Molecular Therapy — Oncolytics · 37 citations
https://doi.org/10.1016/j.omto.2018.04.002
Advances in oncolytic virotherapy
2022 · Communications Medicine · 31 citations
https://doi.org/10.1038/s43856-022-00098-4
Oncolytic measles vaccines encoding PD-1 and PD-L1 checkpoint blocking antibodies to increase tumor-specific T cell memory
2021 · Molecular Therapy — Oncolytics · 17 citations
https://doi.org/10.1016/j.omto.2021.11.020
Improving immunovirotherapies: the intersection of mathematical modelling and experiments
2022 · ImmunoInformatics · 12 citations
https://doi.org/10.1016/j.immuno.2022.100011
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat